{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:35:16Z","timestamp":1762508116268,"version":"3.40.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T00:00:00Z","timestamp":1588982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T00:00:00Z","timestamp":1588982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1006663","APP1135898"],"award-info":[{"award-number":["APP1006663","APP1135898"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00262-020-02597-6","type":"journal-article","created":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T08:02:18Z","timestamp":1589011338000},"page":"1959-1972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Therapeutic ISCOMATRIX\u2122 adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3989-9570","authenticated-orcid":false,"given":"Adele M.","family":"Barr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anabel","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Prato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle T.","family":"Belz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Maraskovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Baz Morelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,9]]},"reference":[{"issue":"2","key":"2597_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2):205\u2013214. https:\/\/doi.org\/10.1016\/j.cell.2015.03.030","journal-title":"Cell"},{"issue":"1","key":"2597_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD (2019) Jemal A (2019) Cancer statistics. CA Cancer J Clin 69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2597_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, Investigators IS (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411\u2013422. https:\/\/doi.org\/10.1056\/NEJMoa1001294","journal-title":"N Engl J Med"},{"issue":"13","key":"2597_CR4","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.18.02031","volume":"37","author":"JL Gulley","year":"2019","unstructured":"Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW (2019) Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J Clin Oncol 37(13):1051\u20131061. https:\/\/doi.org\/10.1200\/JCO.18.02031","journal-title":"J Clin Oncol"},{"issue":"6230","key":"2597_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348(6230):56\u201361. https:\/\/doi.org\/10.1126\/science.aaa8172","journal-title":"Science"},{"issue":"8","key":"2597_CR6","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/14760584.2018.1506332","volume":"17","author":"JM Collins","year":"2018","unstructured":"Collins JM, Redman JM, Gulley JL (2018) Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy. Expert Rev Vaccines 17(8):697\u2013705. https:\/\/doi.org\/10.1080\/14760584.2018.1506332","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"2597_CR7","doi-asserted-by":"publisher","first-page":"e0197694","DOI":"10.1371\/journal.pone.0197694","volume":"13","author":"PO Ilyinskii","year":"2018","unstructured":"Ilyinskii PO, Kovalev GI, O'Neil CP, Roy CJ, Michaud AM, Drefs NM, Pechenkin MA, Fu FN, Johnston LPM, Ovchinnikov DA, Kishimoto TK (2018) Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy. PLoS ONE 13(6):e0197694. https:\/\/doi.org\/10.1371\/journal.pone.0197694","journal-title":"PLoS ONE"},{"key":"2597_CR8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3389\/fimmu.2015.00605","volume":"6","author":"CI Dahlberg","year":"2015","unstructured":"Dahlberg CI, Sarhan D, Chrobok M, Duru AD, Alici E (2015) Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity. Front Immunol 6:605. https:\/\/doi.org\/10.3389\/fimmu.2015.00605","journal-title":"Front Immunol"},{"key":"2597_CR9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3389\/fimmu.2015.00578","volume":"6","author":"K Rezvani","year":"2015","unstructured":"Rezvani K, Rouce RH (2015) The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol 6:578. https:\/\/doi.org\/10.3389\/fimmu.2015.00578","journal-title":"Front Immunol"},{"key":"2597_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","volume":"9","author":"RS Mehta","year":"2018","unstructured":"Mehta RS, Rezvani K (2018) Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front Immunol 9:283. https:\/\/doi.org\/10.3389\/fimmu.2018.00283","journal-title":"Front Immunol"},{"key":"2597_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3389\/fimmu.2015.00601","volume":"6","author":"C Chester","year":"2015","unstructured":"Chester C, Fritsch K, Kohrt HE (2015) Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy. Front Immunol 6:601. https:\/\/doi.org\/10.3389\/fimmu.2015.00601","journal-title":"Front Immunol"},{"issue":"1","key":"2597_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.imbio.2015.07.012","volume":"222","author":"J Pahl","year":"2017","unstructured":"Pahl J, Cerwenka A (2017) Tricking the balance: NK cells in anti-cancer immunity. Immunobiology 222(1):11\u201320. https:\/\/doi.org\/10.1016\/j.imbio.2015.07.012","journal-title":"Immunobiology"},{"issue":"7","key":"2597_CR13","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andre","year":"2018","unstructured":"Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Blery M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E (2018) Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK Cells. Cell 175(7):1731\u20131743. https:\/\/doi.org\/10.1016\/j.cell.2018.10.014","journal-title":"Cell"},{"issue":"6383","key":"2597_CR14","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1126\/science.aat2184","volume":"359","author":"A Cerwenka","year":"2018","unstructured":"Cerwenka A, Lanier LL (2018) Natural killers join the fight against cancer. Science 359(6383):1460\u20131461. https:\/\/doi.org\/10.1126\/science.aat2184","journal-title":"Science"},{"issue":"5","key":"2597_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/imcb.12045","volume":"96","author":"J Rautela","year":"2018","unstructured":"Rautela J, Souza-Fonseca-Guimaraes F, Hediyeh-Zadeh S, Delconte RB, Davis MJ, Huntington ND (2018) Molecular insight into targeting the NK cell immune response to cancer. Immunol Cell Biol 96(5):477\u2013484. https:\/\/doi.org\/10.1111\/imcb.12045","journal-title":"Immunol Cell Biol"},{"issue":"8","key":"2597_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.vaccine.2003.09.014","volume":"22","author":"A Lenarczyk","year":"2004","unstructured":"Lenarczyk A, Le TT, Drane D, Malliaros J, Pearse M, Hamilton R, Cox J, Luft T, Gardner J, Suhrbier A (2004) ISCOM based vaccines for cancer immunotherapy. Vaccine 22(8):963\u2013974","journal-title":"Vaccine"},{"issue":"8","key":"2597_CR17","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1158\/1078-0432.CCR-03-0245","volume":"10","author":"E Maraskovsky","year":"2004","unstructured":"Maraskovsky E, Sjolander S, Drane DP, Schnurr M, Le TT, Mateo L, Luft T, Masterman KA, Tai TY, Chen Q, Green S, Sjolander A, Pearse MJ, Lemonnier FA, Chen W, Cebon J, Suhrbier A (2004) NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res 10(8):2879\u20132890","journal-title":"Clin Cancer Res"},{"key":"2597_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120692","author":"EA Thompson","year":"2018","unstructured":"Thompson EA, Ols S, Miura K, Rausch K, Narum DL, Spangberg M, Juraska M, Wille-Reece U, Weiner A, Howard RF, Long CA, Duffy PE, Johnston L, O'Neil CP, Lore K (2018) TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.120692","journal-title":"JCI Insight"},{"issue":"21","key":"2597_CR19","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.vaccine.2016.03.057","volume":"34","author":"Z Julier","year":"2016","unstructured":"Julier Z, de Titta A, Grimm AJ, Simeoni E, Swartz MA, Hubbell JA (2016) Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses. Vaccine 34(21):2453\u20132459. https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.057","journal-title":"Vaccine"},{"issue":"7","key":"2597_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1586\/14760584.2013.811185","volume":"12","author":"A Mount","year":"2013","unstructured":"Mount A, Koernig S, Silva A, Drane D, Maraskovsky E, Morelli AB (2013) Combination of adjuvants: the future of vaccine design. Expert Rev Vaccines 12(7):733\u2013746. https:\/\/doi.org\/10.1586\/14760584.2013.811185","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"2597_CR21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/vaccines3020390","volume":"3","author":"H Shirota","year":"2015","unstructured":"Shirota H, Tross D, Klinman DM (2015) CpG Oligonucleotides as cancer vaccine adjuvants. Vaccines (Basel) 3(2):390\u2013407. https:\/\/doi.org\/10.3390\/vaccines3020390","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"2597_CR22","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.4049\/jimmunol.1402228","volume":"194","author":"A Silva","year":"2015","unstructured":"Silva A, Mount A, Krstevska K, Pejoski D, Hardy MP, Owczarek C, Scotney P, Maraskovsky E, Baz Morelli A (2015) The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo. J Immunol 194(5):2199\u20132207. https:\/\/doi.org\/10.4049\/jimmunol.1402228","journal-title":"J Immunol"},{"issue":"16","key":"2597_CR23","first-page":"3325","volume":"57","author":"BA Foster","year":"1997","unstructured":"Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM (1997) Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57(16):3325\u20133330","journal-title":"Cancer Res"},{"issue":"8","key":"2597_CR24","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1073\/pnas.92.8.3439","volume":"92","author":"NM Greenberg","year":"1995","unstructured":"Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92(8):3439\u20133443","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2597_CR25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/icb.2010.131","volume":"89","author":"S Prato","year":"2011","unstructured":"Prato S, Mintern JD, Lahoud MH, Huang DC, Villadangos JA (2011) Induction of antigen-specific effector-phase tolerance following vaccination against a previously ignored B-cell lymphoma. Immunol Cell Biol 89(5):595\u2013603. https:\/\/doi.org\/10.1038\/icb.2010.131","journal-title":"Immunol Cell Biol"},{"issue":"5","key":"2597_CR26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1586\/14760584.6.5.761","volume":"6","author":"D Drane","year":"2007","unstructured":"Drane D, Gittleson C, Boyle J, Maraskovsky E (2007) ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines 6(5):761\u2013772. https:\/\/doi.org\/10.1586\/14760584.6.5.761","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"2597_CR27","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207(10):2187\u20132194. https:\/\/doi.org\/10.1084\/jem.20100643","journal-title":"J Exp Med"},{"issue":"2","key":"2597_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ijc.2910160204","volume":"16","author":"RB Herberman","year":"1975","unstructured":"Herberman RB, Nunn ME, Lavrin DH (1975) Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 16(2):216\u2013229","journal-title":"Int J Cancer"},{"issue":"2","key":"2597_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/eji.1830050208","volume":"5","author":"R Kiessling","year":"1975","unstructured":"Kiessling R, Klein E, Wigzell H (1975) \"Natural\" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 5(2):112\u2013117. https:\/\/doi.org\/10.1002\/eji.1830050208","journal-title":"Eur J Immunol"},{"issue":"6","key":"2597_CR30","doi-asserted-by":"crossref","first-page":"862","DOI":"10.4049\/jimmunol.111.6.1862","volume":"111","author":"RK Oldham","year":"1973","unstructured":"Oldham RK, Herberman RB (1973) Evaluation of cell-mediated cytotoxic reactivity against tumor associated antigens with 125I-iododeoxyuridine labeled target cells. J Immunol 111(6):862\u2013871","journal-title":"J Immunol"},{"issue":"6","key":"2597_CR31","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.4049\/jimmunol.161.6.2817","volume":"161","author":"SG Shaw","year":"1998","unstructured":"Shaw SG, Maung AA, Steptoe RJ, Thomson AW, Vujanovic NL (1998) Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol 161(6):2817\u20132824","journal-title":"J Immunol"},{"issue":"1","key":"2597_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4049\/jimmunol.172.1.138","volume":"172","author":"KN Schmidt","year":"2004","unstructured":"Schmidt KN, Leung B, Kwong M, Zarember KA, Satyal S, Navas TA, Wang F, Godowski PJ (2004) APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J Immunol 172(1):138\u2013143","journal-title":"J Immunol"},{"issue":"6013","key":"2597_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331(6013):44\u201349. https:\/\/doi.org\/10.1126\/science.1198687","journal-title":"Science"},{"issue":"21","key":"2597_CR34","first-page":"4687","volume":"57","author":"JR Gingrich","year":"1997","unstructured":"Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM (1997) Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57(21):4687\u20134691","journal-title":"Cancer Res"},{"issue":"10","key":"2597_CR35","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/ni1112","volume":"5","author":"A Iwasaki","year":"2004","unstructured":"Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5(10):987\u2013995. https:\/\/doi.org\/10.1038\/ni1112","journal-title":"Nat Immunol"},{"issue":"1","key":"2597_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1365-2567.2004.01878.x","volume":"112","author":"H Hochrein","year":"2004","unstructured":"Hochrein H, Wagner H (2004) Of men, mice and pigs: looking at their plasmacytoid dendritic cells [corrected]. Immunology 112(1):26\u201327. https:\/\/doi.org\/10.1111\/j.1365-2567.2004.01878.x","journal-title":"Immunology"},{"issue":"7","key":"2597_CR37","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1158\/0008-5472.CAN-09-1162","volume":"70","author":"AI Chin","year":"2010","unstructured":"Chin AI, Miyahira AK, Covarrubias A, Teague J, Guo B, Dempsey PW, Cheng G (2010) Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res 70(7):2595\u20132603. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1162","journal-title":"Cancer Res"},{"issue":"8","key":"2597_CR38","first-page":"2081","volume":"60","author":"RP Ciavarra","year":"2000","unstructured":"Ciavarra RP, Somers KD, Brown RR, Glass WF, Consolvo PJ, Wright GL, Schellhammer PF (2000) Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer. Cancer Res 60(8):2081\u20132084","journal-title":"Cancer Res"},{"issue":"5","key":"2597_CR39","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1084\/jem.184.5.1953","volume":"184","author":"E Maraskovsky","year":"1996","unstructured":"Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 184(5):1953\u20131962","journal-title":"J Exp Med"},{"issue":"3","key":"2597_CR40","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1182\/blood.V96.3.878","volume":"96","author":"E Maraskovsky","year":"2000","unstructured":"Maraskovsky E, Daro E, Roux E, Teepe M, Maliszewski CR, Hoek J, Caron D, Lebsack ME, McKenna HJ (2000) In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 96(3):878\u2013884","journal-title":"Blood"},{"issue":"4","key":"2597_CR41","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","volume":"28","author":"N Guerra","year":"2008","unstructured":"Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH (2008) NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28(4):571\u2013580. https:\/\/doi.org\/10.1016\/j.immuni.2008.02.016","journal-title":"Immunity"},{"issue":"10","key":"2597_CR42","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1172\/JCI69369","volume":"123","author":"G Liu","year":"2013","unstructured":"Liu G, Lu S, Wang X, Page ST, Higano CS, Plymate SR, Greenberg NM, Sun S, Li Z, Wu JD (2013) Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J Clin Investig 123(10):4410\u20134422. https:\/\/doi.org\/10.1172\/JCI69369","journal-title":"J Clin Investig"},{"issue":"8","key":"2597_CR43","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1158\/0008-5472.CAN-15-1965","volume":"76","author":"C Pasero","year":"2016","unstructured":"Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P, Paciencia-Gros M, Poizat F, Bentobji M, Azario-Cheillan F, Walz J, Salem N, Brunelle S, Moretta A, Olive D (2016) Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity. Cancer Res 76(8):2153\u20132165. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1965","journal-title":"Cancer Res"},{"issue":"5","key":"2597_CR44","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/icb.2011.71","volume":"90","author":"NS Wilson","year":"2012","unstructured":"Wilson NS, Yang B, Morelli AB, Koernig S, Yang A, Loeser S, Airey D, Provan L, Hass P, Braley H, Couto S, Drane D, Boyle J, Belz GT, Ashkenazi A, Maraskovsky E (2012) ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol Cell Biol 90(5):540\u2013552. https:\/\/doi.org\/10.1038\/icb.2011.71","journal-title":"Immunol Cell Biol"},{"issue":"5","key":"2597_CR45","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0090-4295(99)80301-X","volume":"46","author":"RA Blades","year":"1995","unstructured":"Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL (1995) Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46(5):681\u2013686. https:\/\/doi.org\/10.1016\/S0090-4295(99)80301-X(discussion 686\u2013687)","journal-title":"Urology"},{"key":"2597_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.352","author":"EJ Cheadle","year":"2017","unstructured":"Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J, Illidge TM (2017) A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. Leukemia. https:\/\/doi.org\/10.1038\/leu.2016.352","journal-title":"Leukemia"},{"issue":"7","key":"2597_CR47","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nm0795-649","volume":"1","author":"LD Falo Jr","year":"1995","unstructured":"Falo LD Jr, Kovacsovics-Bankowski M, Thompson K, Rock KL (1995) Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med 1(7):649\u2013653. https:\/\/doi.org\/10.1038\/nm0795-649","journal-title":"Nat Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02597-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02597-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02597-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T19:56:17Z","timestamp":1744055777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02597-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,9]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2597"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02597-6","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2020,5,9]]},"assertion":[{"value":"18 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Adele Barr, Sandro Prato, Adriana Baz Morelli and Eugene Maraskovsky are currently employees of CSL Ltd.\u00a0At the time of completing this work Anabel Silva was an employee of CSL Ltd. The authors declare that there are no other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was carried out according to the \u2018Australian Code for the Responsible Conduct of Research 2018\u2019. All animal studies were approved by the CSL Limited\/Pfizer Australia Animal Ethics Committee (Melbourne, VIC, Australia). Experiments performed were outlined in approved animal ethics applications AEC (Animal Ethics Committee) register numbers 863, 831, 880, 966 and 981.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"C57BL\/6J and B6.SJL\/J-PTPRCa mice used in these experiments were bred at the Bio21 Institute (Melbourne, VIC, Australia). C57BL\/6 Tg(TRAMP)8247Ng\/J and B6.129S7-Ifngtm1Ts\/J mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal source"}},{"value":"The B16-OVA melanoma cell line (clone MO5, []) was kindly provided by A. Surhbier (QIMR Berghofer, Brisbane, QLD, Australia). The TRAMP-C1 cell line was purchased from American Type Culture Collection (ATCC\u00ae) (CRL-2730). The E\u00b5-myc-GFP-OVA lymphoma cell line was kindly provided by the creator of this lymphoma cell line, J. Villadangos [] (The University of Melbourne, Melbourne, Australia). Tumor cell lines have been cultured no longer than 3\u00a0weeks after thawing and used for the experiments without any further authentication. All cell lines were routinely tested for mycoplasma contamination with PCR technique.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentication"}}]}}